NorgesInvestor
NorgesInvestor, established in 1996, is a Norwegian asset management firm headquartered in Oslo with an additional office in Stockholm. The company specializes in strategic and financial value creation through various investment activities. These include private equity funds, where they actively manage investments in mature and growth companies across sectors such as telecommunications, information technology, retail, and manufacturing in Norway and Sweden. They also offer discretionary wealth management services and invest in listed securities. NorgesInvestor is privately-owned, financially robust, and independent.
Algeta ASA is an oncology company based in Oslo, Norway, dedicated to developing targeted therapies for cancer patients using its innovative alpha-pharmaceutical platform. The company's lead product, radium-223 dichloride, has successfully completed Phase III clinical trials for treating castration-resistant prostate cancer with bone metastases. Additionally, Algeta is advancing the development of thorium-227 conjugates, which involve linking the alpha-emitter to tumor-targeting molecules, currently in the preclinical phase. Algeta has established a collaboration with Bayer Pharma AG for the global development and commercialization of radium-223. Founded in 1997, the company originally operated under the name Anticancer Therapeutic Inventions AS before rebranding as Algeta ASA in 2003.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.